Nykode Therapeutics Receives US FDA’s IND Approval for P-II Trial (VB-C-04) to Evaluate VB10.16 in HPV16-Positive Cervical Cancer
Shots:
- The US FDA has approved an IND application for the P-II trial (VB-C-04) to evaluate VB10.16 (off-the-shelf therapeutic cancer vaccine) + Roche’s Tecentriq for HPV16+, PD-L1+, recurrent or metastatic cervical cancer. The trial is expected to initiate in Q4’23
- Atezolizumab is supplied by Roche while Nykode retains all commercial rights to VB10.16 globally. The P-II trial results of VB10.16 in combination with atezolizumab for advanced cervical cancer showed mOS not reached but ≥25mos. at the time of analysis in PD-L1+ patients
- In the P-I/IIa, the therapy showed a significant correlation b/w immune responses and clinical responses with favorable clinical data in pre-cancerous HPV16-induced high-grade cervical intraepithelial neoplasia
Ref: Globenewswire | Image: Nykode
Related News:- Nykode Therapeutics Expands its Clinical Collaboration and Supply Agreement with Roche to Evaluate VB10.16 for Advanced Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
